Omada Health
OMDA
11.87
-0.63
-5.04%
Omada Health
US · OMDA
#3099 by market cap
Listed 2025
11.87
-0.63
-5.04%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.24, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +53.25% YoY
Margins
- Gross margin
- 65.69%
- Operating margin
- -4.60%
- Net margin
- -4.91%
Key ratios & quality
- Altman Z-Scorei
- 5.24
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 89.19M | 122.78M | 169.80M | 260.21M |
| Gross profit | 42.79M | 69.97M | 102.88M | 170.94M |
| Selling & admin expenses | 88.97M | 102.23M | 110.61M | 142.23M |
| Research & development | 26.17M | 33.74M | 35.92M | 40.68M |
| Operating profit | -72.35M | -66.00M | -43.65M | -11.97M |
| Pretax profit | -72.52M | -67.51M | -47.14M | -12.78M |
| Tax | 0 | 0 | 0 | 0 |
| Net profit | -72.52M | -67.51M | -47.14M | -12.78M |
| Basic EPS | -2 | -1 | -1 | 0 |
| Diluted EPS | -1.52 | -1.41 | -0.85 | -0.35 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 61.37M | 68.03M | 75.85M | 78.05M | 87.84M | 91.31M |
| Gross profit | 40.31M | 45.07M | 53.66M | 48.69M | 63.79M | 69.28M |
| Selling & admin expenses | 34.63M | 37.28M | 38.83M | 40.78M | 45.61M | 49.19M |
| Research & development | 10.02M | 10.30M | 11.55M | 12.70M | 14.63M | 15.27M |
| Operating profit | -4.34M | -2.51M | 3.28M | -4.78M | 3.55M | 4.82M |
| Pretax profit | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M | 6.55M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M | 6.55M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.24 | -0.06 | 0.08 | -0.05 | 0.08 | 0.10 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 188.56M | 142.88M | 113.06M | 272.93M |
| Cash & ST investments | 168.12M | 115.64M | 76.39M | 222.04M |
| Inventory | 3.54M | 3.61M | 3.30M | 4.49M |
| Total assets | 221.80M | 175.08M | 150.89M | 305.41M |
| Total current liabilities | 34.51M | 43.79M | 53.95M | 75.73M |
| Short-term debt | 648.00K | 787.00K | 415.00K | -- |
| Long-term debt | 28.90M | 29.38M | 29.77M | -- |
| Total liabilities | 66,193,000.00 | 76,158,000.00 | 535,295,000.00 | 75,726,000.00 |
| Total equity | 155.61M | 98.92M | -384.40M | 229.68M |
| Retained earnings | -329.32M | -396.83M | -443.97M | -456.74M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 271.11M | 254.90M | 272.93M | 269.43M | 294.91M | 315.06M |
| Cash & ST investments | 223.15M | 198.63M | 222.04M | 211.77M | 221.71M | 243.15M |
| Inventory | 3.47M | 3.15M | 4.49M | 3.83M | 4.12M | 4.88M |
| Total assets | 302.97M | 287.47M | 305.41M | 302.80M | 328.22M | 348.54M |
| Total current liabilities | 57.99M | 70.12M | 75.73M | 68.68M | 75.48M | 75.38M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | 29.97M | -- | -- | -- | -- | -- |
| Total liabilities | 88,757,000.00 | 70,123,000.00 | 75,726,000.00 | 68,680,000.00 | 75,483,000.00 | 75,379,000.00 |
| Total equity | 214.21M | 217.35M | 229.68M | 234.12M | 252.74M | 273.16M |
| Retained earnings | -458.73M | -461.90M | -456.74M | -459.71M | -454.42M | -447.87M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -68.98M | -49.74M | -34.18M | 18.25M |
| Depreciation & amortization | 4.33M | 4.45M | 4.80M | 5.49M |
| Free cash flow | -71.70M | -52.66M | -38.04M | 12.42M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.74M | 0 | 0 | 160.53M |
| Ending cash balance | 168.12M | 115.64M | 76.39M | 222.04M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.86M | 10.13M | 21.38M | -11.83M | 4.01M | 15.14M |
| Depreciation & amortization | 1.35M | 1.36M | 1.45M | 1.51M | 1.58M | 1.68M |
| Free cash flow | 1.61M | 8.15M | 20.03M | -13.39M | 2.34M | 13.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 159.61M | 0 | 0 | 3.25M | -3.25M | 0 |
| Ending cash balance | 223.15M | 198.63M | 222.04M | 211.77M | 221.71M | 243.15M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -32.70 | -34.02 | -29.04 | -5.60 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -76.60 | -51.15 | -25.11 | -3.94 |
| FCF / sales %i | -- | -- | -- | 4.77 |
| Current ratioi | 5.46 | 3.26 | 2.10 | 3.60 |
| Quick ratioi | 5.21 | 3.02 | 1.86 | 3.40 |
| Debt / assetsi | 13.89 | 17.47 | 20.01 | 0.00 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -16.26 | -13.35 | -9.46 | -4.04 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 42.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -15.14 | -12.14 | -- | -- | 1.84 | 5.72 |
| ROA %i | -10.71 | -9.18 | -5.60 | -2.84 | 1.36 | 4.41 |
| ROIC %i | -12.13 | -12.13 | -- | -- | -1.19 | 2.80 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -13.26 | -9.71 | -3.94 | -1.70 | 1.52 | 4.31 |
| FCF / sales %i | -- | -- | 4.77 | 5.79 | 5.53 | 6.75 |
| Current ratioi | 4.68 | 3.64 | 3.60 | 3.92 | 3.91 | 4.18 |
| Quick ratioi | 4.42 | 3.42 | 3.40 | 3.67 | 3.69 | 3.87 |
| Debt / assetsi | 9.89 | 0.00 | 0.00 | -- | -- | -- |
| LT debt / equityi | 13.99 | -- | -- | -- | -- | -- |
| Interest coveragei | -6.31 | -6.24 | -4.04 | -3.26 | 11.82 | 46.71 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Virtual care program product offering100.00%
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Omada Health discussion 0 comments